VEGFA and amyotrophic lateral sclerosis: Over the last decades, a large body of evidence has supported the administration of neurotrophic factors (such as glial cell line-derived neurotrophic factor [GDNF], insulin-like-growth factor [IGF-1], ciliary neurotrophic factor [CNTF] and vascular endothelial growth factor [VEGF]) to ameliorate the ALS disease process, but with limited success in terms of a clinical use for this approach (Henriques et al., 2010).